Pfizer's US $5.2 billion purchase of creboro ointment and its application for listing in China
-
Last Update: 2020-02-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On February 10, Pfizer's application for listing creborough ointment in China was accepted by CDE Crisaborole is a non steroidal PDE4 inhibitor obtained by Pfizer in May 2016 for us $5.2 billion to acquire ANACOR On December 14, 2016, the drug was approved by the FDA for use in the treatment of mild to moderate atopic dermatitis in children and adults The trade name is eucrisa In addition, the drug was approved in Canada, Australia and Israel In 2019, the drug sold $138 million Atopic dermatitis, commonly known as eczema, is a chronic recurrent skin disease, mainly manifested as severe pruritus, eczema like lesions and dry skin, which is prone to occur in children, most of them in infancy According to statistics, about 10% of adults and 20% of children in the world are affected by atopic dermatitis, 45% of cases occurred six months ago, 60% of cases occurred before the age of one year, 85% of cases occurred before the age of five years, and about 50% of children will have relapses after puberty and adulthood Previously, the drug has been included in the list of the second batch of clinically urgent overseas new drugs.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
